Nkarta Inc (NKTX) Stock Price, Quote & News

Company Profile

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for...

Industry: Biotechnology

Sector: Healthcare

Phone: 925 407 1049

Website: www.nkartatx.com

Address:

1150 Veterans Boulevard, South San Francisco, United States

SwamiGodu Dec. 4 at 7:11 PM

$NKTX Just listened to the fireside chat. Switched to "flu/cy" from "flu" alone at some point during current trial and pushed out reporting of results until "sometime next year." As previously reported, cash runway extends into 2029. Allows them to be "opportunistic" about raising additional funds. No mention of need to acquire an asset. Everything positive, upbeat.

0 · Reply

BioEmerging Dec. 4 at 5:52 PM

$NKTX company needs to acquire an asset. It has the cash which is not getting valued.

0 · Reply

jerzypawlik Dec. 4 at 5:51 PM

$NKTX On conferences like this, they have to keep tied lips. They can't release any information. So this is normal, and news might come after the conference. Load and don't question it this is going to go ballistic soon.

0 · Reply

SwamiGodu Dec. 4 at 5:30 PM

$NKTX Were on the agenda for 10:50 this morning. Anyone know wat they said? Whatever it was, hasn't moved the stock.

0 · Reply

jerzypawlik Dec. 3 at 12:26 AM

$NKTX I hope they will shed some light on the near future at the conference on December 4th.

1 · Reply

Iightning Nov. 26 at 5:43 AM

1ightning® Options Trade Alert (Actionable) | Buy $NKTX Dec 19 $2 Call | Enter: $0.06 Exit: $0.11 | Profit: 82.50% ROI | https://1ightning.com

1 · Reply

Iightning Nov. 25 at 3:51 PM

1ightning® Options Trade Alert (Actionable) | Buy $NKTX Dec 19 $2 Call | Enter: $0.06 Exit: $0.11 | Profit: 82.50% ROI | https://1ightning.com

0 · Reply

RandomInternetDude Nov. 25 at 2:39 PM

$NKTX According to their website, nkarta will be participating in the Evercore Healthcare Conference In Miami Dec 4, 2025 at 10:50 AM EST https://ir.nkartatx.com/events/event-details/evercore-healthcare-conference-miami

0 · Reply

Iightning Nov. 25 at 4:45 AM

1ightning® Options Trade Alert (Actionable) | Buy $NKTX Dec 19 $2 Call | Enter: $0.06 Exit: $0.11 | Profit: 82.50% ROI | https://1ightning.com

0 · Reply

hopeteen Nov. 24 at 2:31 PM

$NKTX They don’t respond to investor emails. Management and public relations are poor. No profit for years. They change the release date of clinical trial results at the last minute. Loss of time

0 · Reply

Nkarta to Participate in Evercore Healthcare Conference

Nov 22, 2025, 8:28 AM EST - 12 days ago

Nkarta: Pushing Deeper And Deeper Into A Discount Vs. Their Holdings, For No Real Reason

Nov 10, 2025, 4:01 PM EST - 24 days ago

Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights

Oct 30, 2025, 1:14 PM EDT - 5 weeks ago

Nkarta to Participate in November Investor Conferences

Oct 22, 2025, 10:07 AM EDT - 6 weeks ago

Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting

Sep 2, 2025, 8:01 AM EDT - 3 months ago

Nkarta to Participate in a September Investor Conference

Aug 12, 2025, 4:01 PM EDT - 4 months ago

Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights

Jul 23, 2025, 8:01 AM EDT - 4 months ago

Nkarta to Participate in the H.C. Wainwright “HCW@Home” Series

Jul 22, 2025, 12:40 AM EDT - 4 months ago

Nkarta: Holding Its Support Steady Ahead Of First Data Readouts In 2025

Jun 6, 2025, 8:52 AM EDT - 6 months ago

Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus

May 15, 2025, 3:46 PM EDT - 7 months ago

Nkarta Downgraded, Analyst Cites Competitive Pressure In Autoimmune Space

May 14, 2025, 4:01 PM EDT - 7 months ago

Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights

Apr 1, 2025, 8:01 AM EDT - 8 months ago

Nkarta to Participate in an April Investor Conference

Mar 31, 2025, 10:41 AM EDT - 8 months ago

Nkarta: Grinding Lower, Trying To Find Support

Mar 31, 2025, 10:15 AM EDT - 8 months ago

Nkarta: Betting On The Turnaround

Mar 27, 2025, 12:50 PM EDT - 9 months ago

Why Is Autoimmune Disease Focused Nkarta Stock Trading Higher On Thursday?

Mar 26, 2025, 4:01 PM EDT - 9 months ago

Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

Feb 25, 2025, 8:01 AM EST - 10 months ago

Nkarta to Participate in March Investor Conferences

Dec 5, 2024, 6:01 AM EST - 1 year ago

Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2

Nov 26, 2024, 7:02 AM EST - 1 year ago

Nkarta to Participate in an Upcoming Investor Conference

Nov 7, 2024, 4:02 PM EST - 1 year ago

Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights

Oct 8, 2024, 9:07 AM EDT - 1 year ago

Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month

AMN MRNA

Sep 3, 2024, 4:01 PM EDT - 1 year ago

Nkarta to Participate in Upcoming Investor Conference

Aug 14, 2024, 3:08 PM EDT - 1 year ago

Nkarta: NK Cell Therapy Biotech With Good Standing Targeting R/R NHL Patients

Aug 14, 2024, 12:37 PM EDT - 1 year ago

Why Nkarta Stock Is Soaring Today

Aug 13, 2024, 9:03 PM EDT - 1 year ago

Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

Aug 13, 2024, 4:01 PM EDT - 1 year ago

Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

Jul 24, 2024, 6:00 AM EDT - 1 year ago

Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus Erythematosus

Jul 16, 2024, 6:01 AM EDT - 1 year ago

Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President

Jun 27, 2024, 6:00 AM EDT - 1 year ago

Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications

Jun 13, 2024, 4:01 PM EDT - 1 year ago

Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors

May 25, 2024, 2:20 AM EDT - 1 year ago

Nkarta: Finally An Attractive Valuation

May 9, 2024, 4:01 PM EDT - 1 year ago

Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights

Apr 27, 2024, 10:27 AM EDT - 1 year ago

Nkarta: Down 50% Since March With A Clinical Catalyst Ahead

Apr 8, 2024, 12:55 PM EDT - 1 year ago

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors

Apr 5, 2024, 3:35 PM EDT - 1 year ago

The Law Offices of Frank R. Cruz Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors

Apr 3, 2024, 4:02 PM EDT - 1 year ago

Nkarta to Participate in Upcoming Investor Conferences

Mar 25, 2024, 4:03 PM EDT - 1 year ago

Nkarta: NK Cell Therapy Advancement On Two Fronts

Mar 25, 2024, 6:30 AM EDT - 1 year ago

Nkarta Announces Pricing of $240 Million Underwritten Offering

Mar 21, 2024, 4:01 PM EDT - 1 year ago

Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

Mar 13, 2024, 1:22 PM EDT - 1 year ago

Nkarta's Strategic Advances In Cell Therapy For Autoimmune Disorders

Jan 25, 2024, 12:12 PM EST - 2 years ago

Nkarta: Possible Upside From H1 Update, If Positive

Dec 9, 2023, 8:31 PM EST - 2 years ago

Nkarta Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition

Nov 9, 2023, 4:02 PM EST - 2 years ago

Nkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights

Nov 7, 2023, 8:02 AM EST - 2 years ago

Nkarta to Participate at Upcoming Investor Conferences

Oct 17, 2023, 11:47 AM EDT - 2 years ago

Lupus Therapeutics Announces Partnership to Support the Evaluation of Natural Killer (NK) Cell Therapy in Lupus Nephritis

Oct 17, 2023, 7:01 AM EDT - 2 years ago

Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis

Oct 16, 2023, 4:01 PM EDT - 2 years ago

Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures

Aug 10, 2023, 7:01 AM EDT - 2 years ago

Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights

SwamiGodu Dec. 4 at 7:11 PM

0 · Reply

BioEmerging Dec. 4 at 5:52 PM

$NKTX company needs to acquire an asset. It has the cash which is not getting valued.

0 · Reply

jerzypawlik Dec. 4 at 5:51 PM

0 · Reply

SwamiGodu Dec. 4 at 5:30 PM

$NKTX Were on the agenda for 10:50 this morning. Anyone know wat they said? Whatever it was, hasn't moved the stock.

0 · Reply

jerzypawlik Dec. 3 at 12:26 AM

$NKTX I hope they will shed some light on the near future at the conference on December 4th.

1 · Reply

Iightning Nov. 26 at 5:43 AM

1ightning® Options Trade Alert (Actionable) | Buy $NKTX Dec 19 $2 Call | Enter: $0.06 Exit: $0.11 | Profit: 82.50% ROI | https://1ightning.com

1 · Reply

Iightning Nov. 25 at 3:51 PM

1ightning® Options Trade Alert (Actionable) | Buy $NKTX Dec 19 $2 Call | Enter: $0.06 Exit: $0.11 | Profit: 82.50% ROI | https://1ightning.com

0 · Reply

RandomInternetDude Nov. 25 at 2:39 PM

0 · Reply

Iightning Nov. 25 at 4:45 AM

1ightning® Options Trade Alert (Actionable) | Buy $NKTX Dec 19 $2 Call | Enter: $0.06 Exit: $0.11 | Profit: 82.50% ROI | https://1ightning.com

0 · Reply

hopeteen Nov. 24 at 2:31 PM

$NKTX They don’t respond to investor emails. Management and public relations are poor. No profit for years. They change the release date of clinical trial results at the last minute. Loss of time

0 · Reply

Iightning Nov. 22 at 1:57 AM

1ightning® Options Trade Alert (Actionable) | Buy $NKTX Dec 19 $2 Call | Enter: $0.13 Exit: $0.21 | Profit: 60.89% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 21 at 5:19 AM

1ightning® Options Trade Alert (Actionable) | Buy $NKTX Dec 19 $2 Call | Enter: $0.13 Exit: $0.21 | Profit: 60.89% ROI | https://1ightning.com

0 · Reply

jerzypawlik Nov. 20 at 10:53 PM

$NKTX Right now the hedge funds and MMs are bouncing the ball, back and forth, and cleaning weak retailers. I don't think many left. I already bought 120K shares, and if dip, buying more. In few months this is double digit stock.

0 · Reply

jerzypawlik Nov. 20 at 10:50 PM

$NKTX I take this garbage anytime. Next year will see how this garbage makes me tons of money.

2 · Reply

hopeteen Nov. 20 at 5:06 PM

$NKTX Garbage

0 · Reply

Iightning Nov. 20 at 3:07 AM

1ightning® Options Trade Alert (Actionable) | Buy $NKTX Dec 19 $2 Call | Enter: $0.13 Exit: $0.21 | Profit: 60.89% ROI | https://1ightning.com

0 · Reply

jerzypawlik Nov. 19 at 9:25 PM

$NKTX I told you guys to buy, u didn't listen. News is imminent anytime soon.

0 · Reply

jerzypawlik Nov. 19 at 7:10 PM

$NKTX Over 320 million in cash, enough to continue the operation into 2029. And PT over $12. It's a complete joke that is trading at this price. Load everyone and don't complain.

0 · Reply

jerzypawlik Nov. 19 at 6:56 PM

$NKTX MM'S are driving this down to steal all possible shares from weak retailers. This is the game they make money, and this will rebound quickly and stronger than before. Mark my words.

0 · Reply

jerzypawlik Nov. 19 at 6:53 PM

$NKTX Anyone selling now is the biggest retard I've ever seen. Anyone who holds on and keep adding now, next year will be rich man.

0 · Reply

Lukey63 Nov. 19 at 5:30 PM

$NKTX I see no support for this turd near-term until $1.60 and 1.45. I am long and wrong but still feel there is long-term potential. Will buy below $1.60 if it gets there. Holding my nose at the stink of this company.

0 · Reply

Iightning Nov. 19 at 10:53 AM

1ightning® Options Trade Alert (Actionable) | Buy $NKTX Dec 19 $2 Call | Enter: $0.13 Exit: $0.21 | Profit: 60.89% ROI | https://1ightning.com

0 · Reply

Market Cap	123.59M
Revenue (ttm)	0.00
Net Income (ttm)	-108.79M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	717,400
Avg Vol	955,304
Day's Range	N/A - N/A
Shares Out	71.03M
Stochastic %K	35%
Beta	0.80
Analysts	Strong Sell
Price Target	$11.80